Anti-Pfs25 Antibody Levels Following Vaccination of 5 ��g Pfs25/ISA 51a.

Figshare2015-12-02 更新2026-05-11 收录

数据链接：

https://figshare.com/articles/dataset/_Anti_Pfs25_Antibody_Levels_Following_Vaccination_of_5_g_Pfs25_ISA_51_a_/597367 数据链接链接失效反馈

官方服务：

资源简介：

aThe volunteers were scheduled to receive 2 vaccinations on days 0 and 120.bThese volunteers did not receive the second vaccination.c

创建时间：

2015-12-02

Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901

疫苗临床试验

结核病免疫

Background Development of a tuberculosis vaccine to boost BCG is a major international health priority. SRL172, an inactivated whole cell booster derived from a non-tuberculous mycobacterium, is the o

NIAID Data Ecosystem30

Table_1_Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.docx

非小细胞肺癌免疫治疗

疫苗临床试验

Human telomerase reverse transcriptase (hTERT) is a target antigen for cancer immunotherapy in patients with non-small cell lung cancer (NSCLC). We have tested a novel hTERT vaccine, UV1, designed to

NIAID Data Ecosystem10

First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1

疫苗临床试验

腺病毒载体

BackgroundLive, attenuated viral vectors that express HIV-1 antigens are being investigated as an approach to generating durable immune responses against HIV-1 in humans. We recently developed a repli

Figshare2018-11-14 更新00

Phase I clinical trial dataset: naked DNA SARS-CoV-2 Omicron BA.2 booster vaccine Alveavax-v1.2 against Janssen Ad26.COV2.S comparator, NCT05844202

疫苗临床试验

儿童免疫原性研究

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (Alveavax-v1.2): Results of a first-in-human, open-label, active-controlled, randomized dose-finding study of intradermal and subcutaneous applica

DataCite Commons2025-05-01 更新30

Summary of stool shedding by participants between Day 0 (including pre-challenge) until completion of challenge, according to vaccine group allocation, challenge outcome and phase of shedding.

疫苗临床试验

生物标志物监测

Summary of stool shedding by participants between Day 0 (including pre-challenge) until completion of challenge, according to vaccine group allocation, challenge outcome and phase of shedding.

Figshare2016-08-18 更新10

Anti-Pfs25 Antibody Levels Following Vaccination of 5 ��g Pfs25/ISA 51a.

资源简介：

相关数据集